Wilson Therapeutics AB Report issue

For profit Phase 3
Founded: Stockholm Sweden (2012)
Status: Acquired by Alexion (2018) → now AstraZeneca (2020)

Organization Overview

First Clinical Trial
2014
NCT02273596
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Wilson Therapeutics | Wilson Therapeutics AB

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hepatolenticular Degeneration (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 4